Chicago, August 12, 2020 – With strong momentum in its growing portfolio of life science companies, Paragon Biosciences announced the appointment of Kerensa Jimenez as the new chief executive officer of its capital markets group, Paragon Health Capital (PHC), a registered broker-dealer. With deep experience and a proven track record, Ms. Jimenez will spearhead all financings, mergers [...]
Chicago-Based Developer and Locally Headquartered Data Driven Molecular Engineering Technology Company Partner to Further Shared Vision of Chicago as the Next High-Profile Life Sciences Hub Chicago, August 6, 2020 – Sterling Bay, Chicago’s premier real estate investment and development firm, and Evozyne, LLC, a Chicago-based, privately held, molecular engineering technology company, today announced the [...]
Publication in peer-reviewed journal Science demonstrates the foundation of the company’s evolution-based, data-driven engineering technology to build artificial functional enzymes Chicago, July 23, 2020 – A publication released in the peer-review journal Science today demonstrates the foundation of Evozyne’s evolution-based, data-driven engineering process for building artificial functional enzymes. Founded by life science innovator Paragon Biosciences, Evozyne, a [...]
– Biopharmaceutical company advancing clinical research evaluating novel treatment for Tourette syndrome and childhood-onset fluency disorder – Farmington, Connecticut & Chicago, Illinois – June 3, 2020 – Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the [...]
May 19, 2020 – We are proud to share that Castle Creek Biosciences, a portfolio company of Paragon Biosciences, is featured in Philadelphia Magazine as a company on the cutting edge of cell and gene therapy innovation! The special feature was published as “Yes, Science Can Save Us” in the May 2020 print issue of Philadelphia Magazine [...]
April 29, 2020 – Like all Paragon Biosciences companies, Harmony has understood the importance of establishing a great workplace culture right from their start, with patients at the heart of all they do. In 2017, we at Paragon founded Harmony Biosciences using our proprietary Paragon Innovation Capital™ approach to accelerate development of life science breakthroughs. We identified [...]
The first FDA-cleared artificial intelligence diagnostic system for medical imaging, developed by Qlarity Imaging, a portfolio company of Paragon Biosciences, was selected as a “game-changing” innovation by a panel of global business leaders. Chicago, IL, March 19, 2020 – Qlarity Imaging today announced that QuantX, the first –ever FDA-cleared computer-aided breast cancer diagnosis system in [...]
– Acquisition complements and expands Castle Creek clinical development pipeline to include gene therapy platform – Strategic acquisition to result in advancement of multiple late-stage investigational therapies for epidermolysis bullosa and other rare conditions Exton, PA., December 16, 2019 — Castle Creek Pharmaceutical Holdings, Inc. (“CCP Holdings”), a privately held company focused on developing medicine [...]
The newly created financial services organization was formed to serve the rapid expansion of Paragon Biosciences’ portfolio of life science companies Chicago, IL, August 20, 2019 – Paragon Biosciences LLC – the Chicago-based life science innovator that invests in, builds, and advises bioscience companies – is announcing the formation of Paragon Health Capital, LLC. Brian [...]
The announcement signals accelerated access to more accurate diagnosis for breast cancer patients, stemming from three decades of research at the University of Chicago. Chicago, IL, July 17, 2019 – Paragon Biosciences LLC — the Chicago-based life science innovator that invests in, builds, and advises bioscience companies — is announcing the launch of its seventh [...]
© 2022 Paragon Biosciences LLC | Privacy Policy | Terms of Use
